Land: Singapore
Sprog: engelsk
Kilde: HSA (Health Sciences Authority)
Dapagliflozin propanediol 12.30mg eqv dapagliflozin
ASTRAZENECA SINGAPORE PTE LTD
A10BK01
10mg
TABLET, FILM COATED
Dapagliflozin propanediol 12.30mg eqv dapagliflozin 10mg
ORAL
Prescription Only
AstraZeneca Pharmaceuticals LP
ACTIVE
2014-04-28
FORXIGA TABLET 1 DESCRIPTION FORXIGA (dapagliflozin propanediol) is a potent, highly selective and orally active inhibitor of the human renal sodium-glucose cotransporter 2 (SGLT2), the major transporter responsible for renal glucose reabsorption. Dapagliflozin propanediol is described chemically as D-glucitol, 1,5-anhydro-1-_C_-[4-chloro-3- [(4-ethoxyphenyl)methyl]phenyl]-, (1_S_)-, compounded with (2_S_)-1,2-propanediol, hydrate (1:1:1). The empirical formula is C 21 H 25 ClO 6 • C 3 H 8 O 2 • H 2 O and the molecular weight is 502.98. The structural formula is: FORXIGA is available as a film-coated tablet for oral administration containing the equivalent of 5 mg dapagliflozin as dapagliflozin propanediol, or the equivalent of 10 mg dapagliflozin as dapagliflozin propanediol. 2 THERAPEUTIC INDICATIONS MONOTHERAPY: FORXIGA is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. ADD-ON COMBINATION: FORXIGA is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a sulfonylurea, a DPP4 inhibitor (with or without metformin), or insulin (alone or with up to two oral antidiabetic medications) when the existing therapy, along with diet and exercise, does not provide adequate glycemic control. INITIAL COMBINATION: FORXIGA is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual dapagliflozin and metformin therapy is appropriate. FORXIGA is not indicated for use in patients with type 1 diabetes. FORXIGA should not be used for the treatment of diabetic ketoacidosis. FORXIGA has not been studied in Læs hele dokumentet
1 FORXIGA ® (DAPAGLIFLOZIN) 1. NAME OF THE MEDICINAL PRODUCT FORXIGA tablets, 5 mg and 10 mg. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION FORXIGA 5 mg: Each film-coated tablet contains 5 mg dapagliflozin as dapagliflozin propanediol. FORXIGA 10 mg: Each film-coated tablet contains 10 mg dapagliflozin as dapagliflozin propanediol. 3. PHARMACEUTICAL FORM FORXIGA 5 mg tablets are yellow, biconvex, round, film-coated tablets with “5” debossed on one side and “1427” debossed on the other side. FORXIGA 10 mg tablets are yellow, biconvex, diamond-shaped, film-coated tablets with “10” debossed on one side and “1428” debossed on the other side. For excipients, see section 6.1. Dapagliflozin propanediol is described chemically as D-glucitol, 1,5-anhydro-1- _C_ -[4-chloro-3- [(4-ethoxyphenyl)methyl]phenyl]-, (1 _S_ )-, compounded with (2 _S_ )-1,2-propanediol, hydrate (1:1:1). The empirical formula is C 21 H 25 ClO 6 • C 3 H 8 O 2 • H 2 O and the molecular weight is 502.98. The structural formula is: 4. PHARMACEUTICAL FORM 4.1 THERAPEUTIC INDICATIONS TYPE 2 DIABETES MELLITUS FORXIGA is indicated in adults with type 2 diabetes mellitus to improve glycemic control as an adjunct to diet and exercise. FORXIGA can be given as monotherapy or in combination with other medicinal products indicated for the treatment of type 2 diabetes mellitus. 2 For study results with respect to combination of therapies, effects on glycemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1. HEART FAILURE FORXIGA is indicated in adults with heart failure (NYHA class II-IV) to reduce the risk of cardiovascular death and hospitalization for heart failure (see section 5.1). CHRONIC KIDNEY DISEASE FORXIGA is indicated as an adjunct to standard therapy to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular (CV) death in adults with chronic kidney disease at risk of progression. FORXIGA is not indicated for use in patients with type 1 diabetes. FORXIGA sho Læs hele dokumentet